We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Quantum Phar. | LSE:QP. | London | Ordinary Share | GB00BRTL8Q42 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 84.2374 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 84.00 | 84.75 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 84.2374 | GBX |
Quantum Phar. (QP.) Share Charts1 Year Quantum Phar. Chart |
|
1 Month Quantum Phar. Chart |
Intraday Quantum Phar. Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 31/10/2017 | 08:46 | Quantum Pharma PLC - Charts included. | 632 |
| 12/7/2016 | 09:05 | Quantum Pharma PLC | 904 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 23/10/2017 14:42 by mfhmfh surely a great acquisition by CLIN today and therefore good for QP. shareholders.All IMHO. |
Posted at 10/10/2017 11:24 by mfhmfh Let's hope this helps CLIN's and QP.'s share price:Peel Hunt today upgrades its investment rating on Clinigen Group (LON:CLIN) to buy (from add) and raised its price target to 1350p (from 1200p). |
Posted at 13/9/2017 08:18 by glasshalfull Well CLIN share price reacting adversely to the offer. Down over 4% as I type. Thought it would have been welcomed by CLIN shareholders as earnings accretive per the update I posted from Peel Hunt previously.Value of cash & shares offer now = 80p combined following the fall. I cashed up at the open. Best of luck to holders. Kind regards, GHF |
Posted at 13/9/2017 07:28 by glasshalfull See my recent post 585...Peel Hunt weren't far out!They speculated 84.5p vs 82p announced this morning. 45% of the consideration in cash & as earnings accretive to CLIN I'm hopefully this may result in a boost to the CLIN share price. Irrespective, 23% premium to yesterdays share price isn't too shabby. Kind regards, GHF |
Posted at 23/8/2017 10:06 by rosejs2 Daclam. Management hopefully will be looking after the interests of ALL shareholders...The Instituions will want a more than adequate return for the risk they took both as shareholders and as members of the Lifeboat fundraising..Management will be well rewarded..Note the words 'On a Change of Control' From the November 2016 RNS re option grant: "The LTIP options have been granted to key members of the senior executive team. The options shall vest and become exercisable at an exercise price of 30 pence, either on the mid-market closing share price being greater than 140p for an average of 90 days or on a change of control." CLinigens takeover stratefy is in full swing.with friendly associates consistantly selling small and not so small blocks of QP shares.. Forms 8.3 and 8.5 give insight into their share dealings... Driving down the price is the obvious way forward whilst driving out weak holders.. I suspect the very positive share price of Clinigen will allow them to win the day..It has risen every day for the last week.. My view for what it is worth .. 80p or there abouts will win the day. |
Posted at 22/8/2017 07:55 by rosejs2 R Ball,If you examine the Form 8.3 submitted regarding the proposed Clinigen bid for QP.A number of the current holders are releasing small and not so small amounts of QP shares onto the market... hence the continuing flurry of sells we see on the market board..There is no additions that I can see from current holders..Aviva a signifcant holder in QP.. announced the following on the 16th Aug.. My logic is that the it makes sense for the purchasers of these and other sales to be Clinigen and its associates,, and try and reach if at all possible a 29.9% stake.. Purchases and sales SALE 1,021 SALE 468,909 SALE 5,070 at the folowing prices.. 0.734799 0.734800 0.734801 |
Posted at 16/8/2017 18:52 by duncan doughnut Well I'm home tonight to see my CLIN are in talks to buy my QP. and both shares are up :-] That's a win/win for me.CLIN are trading on a much higher rating that QP. so they can pay a good price and it would still be earnings enhancing. CLIN are making their move now before the growth here really starts to show. I think the new board will hold out for a good price as they haven't even had time to stamp their mark and the company would be taken away from them just as they were going to get the credit. CLIN are 10 times the size of QP., easily in their scope to buy. Bid has to be in 3 fig share price I'd say, if it's to go through. Perhaps after the interims investors will get a better idea of the value here and appreciate what a bid price would need to be. |
Posted at 16/8/2017 17:17 by zed2002 CLIN has about 120m in bank facility. QP. will know the offer price as they have already been told it will be mixture of shares and cash. I believe BOD is thinking over in the Price offered. |
Posted at 09/8/2017 09:24 by a2584728 I expect the share price to increase significantly once the market has digested and understood the huge potential here and at less than 60p a share the upside is massive. Imho of course |
Posted at 08/8/2017 12:40 by rivaldo New interview with the CEO:Extracts: "Quantum Pharma 'fundamentally successful' in simplifying strategy, says chief executive" "Quantum Pharma’s new business model has been hailed as a “fundamental success” by chief executive Chris Rigg, three months after he closed the company’s struggling NuPharm division." "Mr Rigg said that Quantum’s effort to focus its business is now paying off. Speaking to The Journal Mr Rigg said: “The position that the business brought to float was the ability to convert unlicensed medicines to licensed. It then acquired NuPharm. “It was the business I closed, and it was a business that was failing. It was acquired for the right strategic intent but it was failing. “Part of what I have done is to focus and simplify the business. “When you license a product we bring it to market at a lower price than the unlicensed medicine. We can do that as we get a higher market share and manufacture it in bulk. “The aim is to drive into the future the benefits of the license programme to lower prices in the NHS.” Under the renewed strategy Quantum is focusing on its core business. This is largely the supply of unlicensed medications – known as specials – and the creation of licensed products through its Colonis arm. With its network of pharmacies across the UK, Quantum is a market leader in supplying adapted medicines to the market. This process can involve making liquid versions of pills or changing the flavour of medication. One of the key areas for growth for the firm is Colonis and its licensing division. Once a drug successfully attains a UK license the business involves becomes the only one able to distribute the medication to pharmacies. This gives its a major market advantage. As part of the new model Mr Rigg has appointed new management teams to oversee its divisions, including Colonis. “From a control perspective it allows you to focus,” said Rigg. “You can change and make people accountable.” Despite writing off £13.7m as a result of the NuPharm sale, Mr Rigg said investors reacted well to the renewed focus on its core business. The company’s share price reflected his optimism, and following the closure of NuPharm, Quantum’s share price soared from 43p to 60p over seven days. The price has since levelled off and at the time of writing sits at 55.25p." |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
